ColoScape™ Colorectal Cancer Mutation Detection Test is a novel highly sensitive in vitro diagnostic assay using the qPCR-based multi-gene panel for the qualitative detection of colorectal cancer-associated gene mutations in liquid biopsy and FFPE tissue samples. The kit utilizes our XNA technology which leverages a sequence-specific clamp made by xeno-nucleic acid (XNA) to suppress PCR amplification of wild-type DNA template and selectively amplify only mutant DNA template, reaching sensitivity at 0.1% to 0.5% Variant Allele Frequency (VAF) with 10 ng DNA input. The detection kit identifies the presence or absence of mutations in the targeted regions of four colon cancer-associated genes.
The assay can be performed on qPCR instrumentation that is already available in hospital pathology laboratories. Unlike other colorectal cancer tests on the market, ColoScape™ provides a comprehensive profile of the key colorectal cancer ‘driver’ and ‘resistance’ mutations (gene variation landscape) and offers oncologists valuable information to evaluate targeted therapy options. ColoScape™ could also be used to complement existing colorectal cancer detection tests.
Contact DiaCarta to order ColoScape™Colorectal Cancer Mutation Detection Test Service.
Call +1 800-246-8878